The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

Rapid Growth in Market Size

• The PSA test market has seen substantial growth in recent years, expanding from $3.66 billion in 2023 to an estimated $4.13 billion in 2024.
• This growth trend is expected to continue, reaching $6.4 billion by 2028, with a compound annual growth rate (CAGR) of 11.6%.

Drivers of Growth

• Increased awareness about prostate cancer and its screening methods.
• Growing aging population worldwide.
• Advancements in medical and pharmaceutical technology.
• Clinical recommendations favoring regular screenings.

Prostate Cancer Prevalence and Market Impact

• Prostate cancer is a significant health concern globally, with a considerable impact on the PSA test market.
• The American Society of Clinical Oncology (ASCO) reported 288,300 new cases and 34,700 deaths in the US alone in 2023.
• Rising prevalence necessitates effective screening tools, boosting the demand for PSA tests.

Key Players

• Major companies dominating the PSA test market include Siemens AG, F. Hoffmann-La Roche AG, Bayer AG, and Abbott Laboratories, among others.
• These players drive innovation and market growth through strategic developments and acquisitions.

Read More On The Prostate Specific Antigen (PSA) Test Market Report 2024 – https://www.thebusinessresearchcompany.com/report/prostate-specific-antigen-psa-test-global-market-report

Technological Advancements

• Technological innovation is a pivotal trend shaping the PSA test market.
• LynxDx Inc.’s MyProstateScore 2.0, launched in February 2023, exemplifies cutting-edge non-invasive screening technology.
• The test utilizes a combination of 18 biomarkers, offering personalized risk assessments and guiding clinical decisions.

Bayer AG’s Expansion

• Bayer AG’s acquisition of Noria Therapeutics Inc. and PSMA Therapeutics Inc. in June 2021 signifies strategic expansion.
• The move strengthens Bayer’s prostate cancer portfolio and grants access to innovative diagnostic technologies.

Market Segmentation

1. Type: Includes Clinical Laboratory Improvement Amendments (CLIA), Enzyme-Linked Immunosorbent Assay (ELISA), Fluorescence Immunoassay (FIA), and other types.
2. Application: Encompasses screening, post-treatment monitoring, and other applications.
3. End User: Targets hospitals, diagnostic centers, research institutes, and other end users.

Regional Dynamics

• North America dominated the PSA test market in 2023, while Asia-Pacific is expected to witness the fastest growth in the forecast period.
• These regional variations reflect diverse healthcare landscapes and evolving market demands.

Future Trends

• Shift towards biomarker combinations for enhanced accuracy.
• Adoption of point-of-care testing for convenience and accessibility.
• Integration of digital health solutions for streamlined processes.
• Emphasis on early detection and prevention strategies.

Conclusion The prostate-specific antigen (PSA) test market is on an upward trajectory, driven by increasing cancer prevalence, technological innovations, and strategic expansions by key players. With a focus on personalized medicine and early detection, the market is poised for sustained growth, offering promising prospects for stakeholders across the healthcare continuum.

Request for A Sample Of The Global Prostate Specific Antigen (PSA) Test Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=12576&type=smp